Life Technologies, BMS to partner on diagnostics development

Monday, September 17, 2012 01:17 PM

Life Technologies, a global biotech, has entered into a master development agreement with Bristol-Myers Squibb for current and future companion diagnostics projects.

The current agreement constitutes the second collaboration between the two companies and represents another step in Life Technologies' strategy to develop its diagnostic business through internal development, partnerships and select acquisitions. The agreement covers an initial project for oncology and provides for a long-term partnership across a potentially broad range of Life instrument platforms and a wide range of therapeutic areas.

"The pharmaceutical industry is increasingly turning its focus to discovering and delivering targeted, personalized medications," said Ronnie Andrews, president of medical sciences, Life Technologies. "As more and more targeted drugs come onto the market in the next decade, there will be a growing need for diagnostics that can help predict which patients will benefit from which drugs.

Andrews added, “For oncology alone, hundreds of agents are currently in clinical trials. We see strong market opportunity in the robust expansion this will mean for the companion diagnostics space."

Life Technologies possesses a breadth of platforms that can be leveraged in the development of new diagnostics. These platforms span both genetic and proteomic analysis, including next-generation sequencing, Sanger sequencing, qPCR, flow cytometry and immuno-histochemistry. In addition, the company recently announced that its Ion Torrent Personal Genome Machine (PGM(TM)) would be developed for proteomics capabilities.

Share:          
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs